Real World Application of Chemotherapy Response Score in High Grade Serous Cancer of the Ovary

Real World Application of Chemotherapy Response Score in High Grade Serous Cancer of the Ovary

Background: High grade serous cancers (HGSC) of gynecological origin can be treated with neoadjuvant chemotherapy (NACT) and subsequent interval debulking surgery (IDS) when upfront surgery is not feasible. Chemotherapy response score (CRS) was proposed to evaluate on pathological specimens at IDS t...

Full description

Bibliographic Details
Main Authors:	Federico Ferrari, Francesca Cisotto, Angela Gambino, Filippo Alberto Ferrari, Laura Ardighieri, Sara Forte, Enrico Sartori, Franco Odicino
Format:	Article
Language:	English
Published:	IMR Press 2022-06-01
Series:	Clinical and Experimental Obstetrics & Gynecology
Subjects:	ovarian cancer chemotherapy response score debulking surgery
Online Access:	https://www.imrpress.com/journal/CEOG/49/7/10.31083/j.ceog4907147

Similar Items

Prognostic Role of CRS in High Grade Serous Ovarian Tumour Patients Receiving Neoadjuvant Chemotherapy in a Tertiary Care Hospital of Central India
by: Manal Ashraf Ali, et al.
Published: (2022-05-01)

Prognostic Significance of Chemotherapy Response Score in Patients Undergoing Interval Debulking Surgery and Attained Complete Cytoreduction for High-Grade Serous Tubal and Ovarian Carcinoma
by: Anjana J. Santhamma, et al.

Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review)
by: E. V. Sibirskaya, et al.
Published: (2024-05-01)

NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER. MODERN METHODS AND PATIENTS SELECTION CRITERIA
by: A. E. Solopova, et al.
Published: (2016-09-01)

Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction
by: Mackenzie Cummings, et al.
Published: (2022-04-01)

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study
by: Mengmeng Lyu, et al.
Published: (2022-09-01)

Critical Analysis of Advanced High-Grade Serous Epithelial Ovarian Cancer in Women: An Experience of 100 Cases from a Regional Cancer Center in Northeast India
by: Debabrata Barmon, et al.
Published: (2023-10-01)

Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
by: Leonardo Rundo, et al.
Published: (2022-06-01)

Primary versus interval debulking surgery in the management of ovarian cancer patients, current data summary
by: Victoria Psomiadou, et al.
Published: (2022-04-01)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
by: Shi‐Ping Yang, et al.
Published: (2022-07-01)

Perspectives on Ovarian Cancer 1809 to 2022 and Beyond
by: Frank G. Lawton, et al.
Published: (2022-03-01)

Serum Albumin as a Predictor of Survival after Interval Debulking Surgery for Advanced Ovarian Cancer (AOC): A Retrospective Study
by: Dairui Dai, et al.
Published: (2022-02-01)

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
by: Yan Gao, et al.
Published: (2019-09-01)

Long-term multidisciplinary integrative therapy management resulted in favorable outcomes for ovarian cancer during pregnancy: a case report and literature review
by: Tianmin Xu, et al.
Published: (2019-11-01)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
by: Alberto Farolfi, et al.
Published: (2023-08-01)

Prevalence of Serous Tubal Intraepithelial Carcinoma (STIC) at the Time of Postpartum Contraceptive Procedures during Caesarean Delivery
by: Sara Forte, et al.
Published: (2022-09-01)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
by: Xingyu Liu, et al.
Published: (2023-06-01)

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
by: Yong Jae Lee, et al.
Published: (2022-07-01)

CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals
by: Cheng Li, et al.
Published: (2024-05-01)

Optimal debulking surgery in ovarian cancer patients: MRI may predict the necessity of rectosigmoid resection
by: Xiaofang Zhao, et al.
Published: (2024-06-01)

Interval Debulking Surgery for Advanced Ovarian Cancer in Elderly Patients (≥70 y): Does the Age Matter?
by: Ciro Pinelli, et al.
Published: (2021-08-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

Association between alteration of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, cancer antigen-125 and surgical outcomes in advanced stage ovarian cancer patient who received neoadjuvant chemotherapy
by: Ponganun Tuntinarawat, et al.
Published: (2024-04-01)

Postoperative Complications of Upfront Ovarian Cancer Surgery and Their Effects on Chemotherapy Delay
by: Julia Heikkinen, et al.
Published: (2024-09-01)

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
by: Eleonora Ghisoni, et al.
Published: (2018-05-01)

The Feasibility of Cardiophrenic Lymphnode Assessment and Removal in Patients Requiring Diaphragmatic Resection During Interval Debulking Surgery for Ovarian Cancer
by: Ciro Pinelli, et al.
Published: (2021-08-01)

Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes
by: Sue Cheeseman, et al.
Published: (2023-01-01)

Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer
by: Lu Qin, et al.
Published: (2018-06-01)

Does the Performance of Splenectomy as Part of Cytoreductive Surgery Carry a Worse Prognosis Than in Patients Not Receiving Splenectomy? A Propensity Score Analysis and Review of the Literature
by: James Davies, et al.
Published: (2022-01-01)

Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high‐grade serous carcinoma
by: Naoki Kojima, et al.
Published: (2019-08-01)

Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram
by: Wei-feng Liang, et al.
Published: (2020-10-01)

Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis
by: Angela Santoro, et al.
Published: (2022-03-01)

Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study
by: Mengdi Fu, et al.
Published: (2022-01-01)

Prognostic analysis of peritoneal washing cytology during interval debulking surgery in advanced ovarian cancer
by: Kazuki Takasaki, et al.
Published: (2024-08-01)

Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer
by: Merlo Sebastjan, et al.
Published: (2021-08-01)

HIPEC after Interval Debulking Surgery as Best Clinical Practice in Ovarian Cancer Patients: Case Series and Literature Review
by: Stefano Restaino, et al.
Published: (2022-06-01)

Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?
by: Valentina Ghirardi, et al.
Published: (2022-01-01)

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial
by: Jimmy Belotte, et al.
Published: (2024-05-01)

Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer
by: Julia McAdams, et al.
Published: (2024-09-01)